Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.

Cancer chemotherapy and pharmacology - 1 Jul 2012

Shimada Muneaki, Fujiwara Hiroyuki, Sato Shinya, Oishi Tetsuro, Itamochi Hiroaki, Machida Shizuo, Takei Yuji, Harada Tasuku, Suzuki Mitsuaki, Kigawa Junzo

Abstract excerpt

PURPOSE: Although the pharmacokinetic mechanism of nedaplatin (NDP) is similar to carboplatin, the dose of NDP is typically determined by body surface area and not by the area under the curve (AUC). We conducted a phase I study to determine the AUC-calculated optimal dosage of NDP used in combination chemotherapy with irinotecan (CPT-11) for gynecologic malignancies. METHODS: A total of 15 patients who were to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genital Neoplasms, Female

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Nausea

Share to Neutropenia

Share to Organoplatinum Compounds

Source

Identifiers

PMID: 22610355
DOI: 10.1007/s00280-012-1885-z

Genes

NDP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.PMID 22610355Read ↗

The safety and efficacy of nedaplatin and lobaplatin combined with pemetrexed in first-line chemotherapy for locally advanced and advanced lung adenocarcinoma - A retrospective studySemantic proximity Read ↗

[Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].Semantic proximity Read ↗

Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.Semantic proximity Read ↗

Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.Semantic proximity Read ↗

Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1).Semantic proximity Read ↗

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.Semantic proximity Read ↗

Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.Semantic proximity Read ↗

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.Semantic proximity Read ↗

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.Semantic proximity Read ↗

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.